Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer's APP metabolism and phosphorylation of the Vps10-domain protein, SorL1 by Lane, Rachel F et al.
RESEARCH ARTICLE Open Access
Protein kinase C and rho activated coiled coil
protein kinase 2 (ROCK2) modulate Alzheimer’s
APP metabolism and phosphorylation of the
Vps10-domain protein, SorL1
Rachel F Lane
1*, Joshua W Gatson
2, Scott A Small




Background: Generation of the amyloid b (Ab) peptide of Alzheimer’s disease (AD) is differentially regulated
through the intracellular trafficking of the amyloid b precursor protein (APP) within the secretory and endocytic
pathways. Protein kinase C (PKC) and rho-activated coiled-coil kinases (ROCKs) are two “third messenger” signaling
molecules that control the relative utilization of these two pathways. Several members of the Vps family of
receptors (Vps35, SorL1, SorCS1) play important roles in post-trans-Golgi network (TGN) sorting and generation of
APP derivatives, including Ab at the TGN, endosome and the plasma membrane. We now report that Vps10-
domain proteins are candidate substrates for PKC and/or ROCK2 and act as phospho-state-sensitive physiological
effectors for post-TGN sorting of APP and its derivatives.
Results: Analysis of the SorL1 cytoplasmic tail revealed multiple consensus sites for phosphorylation by protein
kinases. SorL1 was subsequently identified as a phosphoprotein, based on sensitivity of its electrophoretic
migration pattern to calf intestine alkaline phosphatase and on its reaction with anti-phospho-serine antibodies.
Activation of PKC resulted in increased shedding of the ectodomains of both APP and SorL1, and this was
paralleled by an apparent increase in the level of the phosphorylated form of SorL1. ROCK2, the neuronal isoform
of another protein kinase, was found to form complexes with SorL1, and both ROCK2 inhibition and ROCK2
knockdown enhanced generation of both soluble APP and Ab.
Conclusion: These results highlight the potential importance of SorL1 in elucidating phospho-state sensitive
mechanisms in the regulation of metabolism of APP and Ab by PKC and ROCK2.
Introduction
Aberrant processing of the Alzheimer’s amyloid precur-
sor protein (APP) is believed to underlie some forms of
Alzheimer’s disease (AD), leading to increased genera-
tion and/or decreased clearance of amyloid beta 42
(Ab42). APP is differentially processed within discrete
intracellular compartments. Metabolism of APP by
either the endocytic pathway or the constitutive secre-
tory pathway is regulated on a moment to moment
basis by the integration of intercellular and intracellular
signals, including membrane depolarization and first
messenger activation of their cognate receptors [for
reviews, see 1-3]. Second messengers such as calcium
and cyclic AMP act via third messengers that are
enzymes that control protein phosphorylation (i.e., pro-
tein kinases and protein phosphatases). Third messen-
gers enzymes implicated in regulating APP metabolism
include protein kinase C (PKC; [4-9]), protein phospha-
tases 1 and 2A (PP1, PP2A; [4-7]), extracellular signal
regulated protein kinase (ERK; [10]), casein kinases (CK;
[11]), Janus kinase (JNK; [12,13]), and rho-associated
coiled-coil protein kinases (ROCK; [14]).
We have a longstanding interest in identifying the
important phospho-state-sensitive physiological effectors
that are targets for these third messengers [4,8,15]. The
obvious candidates for identities of phospho-state sensitive
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itself [4,15]; (ii) the various APP sorting and trafficking
proteins ([8]; this manuscript); and (iii) the secretases
[16,17]. APP phosphorylation at serine 655 was discovered
in 1988 [4], and its physiological role includes regulation
of the interaction of APP with the retromer trafficking
complex [15] and activation of PKC is associated with
increased retromer-mediated transport of APP to the
TGN and decreased Ab generation [15]. In addition to
phosphorylation of APP at serine 655, additional phospho-
acceptor sites have been discovered. Suzuki and colleagues
have documented an important role of the phosphoryla-
tion state of APP threonine 668 in APP maturation and
sorting [reviewed in [3]] while phosphorylation of the
cytoplasmic tail at tyrosine 682 and/or 687 has been
reported to regulate release of the APP intracellular
domain (AICD; [18,19].
APP retrograde trafficking to the TGN and regulation
of Ab generation is dependent on SorL1 interaction
with the core component of the retromer complex,
Vps35 [20,21]. In addditon, we have recently implicated
a second member of the Vps10 family, SorCS1 in retro-
mer-mediated regulation of Ab generation [22]. In the
current study, we have begun investigating the possibili-
ties that some of these Vps10-domain proteins are also
important phospho-state-sensitive modulators of post-
TGN APP metabolism. Herein, we report: (i) that SorL1
is a phosphoprotein; (ii) that both PKC and ROCK2
interact with SorL1; and (iii) that modulation of ROCK2
activity regulates generation of Ab.
Results and Discussion
The subcellular trafficking itinerary for APP
In order to understand how PKC, ROCK, and SorL1
might play important roles in APP metabolism, one
must understand the details of APP sorting and proces-
sing in post TGN compartments. Following exit of
mature APP from the TGN, some APP molecules are
conveyed by the secretory pathway to the plasma mem-
brane where APP can encounter and be cleaved within
the Ab domain by one of the a-secretases; this is the
nonamyloidogenic (non-Ab- f o r m i n g )p a t h w a y )( f o r
review see, [2]). a-secretase cleavage of APP results in
the formation of a cell retained carboxyl terminal frag-
ment (a-CTF) and in the shedding of the APP ectodo-
main, which is also known as soluble APPa (sAPPa).
APP molecules that do not enter the secretory pathway
are targeted to a TGN-localized population of clathrin-
coated vesicles (CCVs). From here, APP is conveyed
into the endocytic pathway where APP can encounter
and be cleaved by the b-secretase, BACE (for b-APP site
cleaving enzyme). BACE cleavage of APP occurs primar-
ily in endosomes, and this step defines APP entry into
the potentially amyloidogenic (Ab-forming) pathway,
resulting in formation of a soluble sAPPb fragment and
a membrane bound b CTF, amino terminus of which is
identical to that of Ab [for review, see [2]]. APP not
cleaved at the plasma membrane by the a-secretases
can be reinternalized into the endocytic pathway thereby
also entering the amyloidogenic pathway.
Within the endosomal system, the a-a n db-CTFs
s e r v ea st h ep r o x i m a t es u b s t r a t e sf o rg-secretase.
g-secretase cleavage of the a-CTF gives rise to secreted
nonamyloidogenic p3 and an intracytoplasmic fragment,
AICD (APP intracellular domain), whereas g-secretase
cleavage of the b-CTF gives rise to Ab and also to
AICD. The g-secretase cleavage is especially important
since this is the step where the major speciation occurs,
giving rise to the heterogeneous carboxyl termini that
define Ab40 and Ab42. Oligomerization and accumula-
tion of Ab42 are believed to be the key inciting events
in causation of AD. Ultimately reducing the time of resi-
dence of APP and/or the b-CTF within the endocytic
pathway decreases Ab generation. Retromer-mediated
trafficking of APP and/or its CTFs away from the endo-
some to the TGN plays a key role in modulating resi-
dence time for APP and/or its CTFs in the endocytic
system [for review, see [2]]. As shown by Small et al
[20], the retromer is especially important in sporadic
AD because hippocampal subregion-specific progression
of AD pathology is linked to a deficiency in the core
component of the retromer, Vps35 [20].
Post-TGN sorting and metabolism of APP is con-
trolled by at least two Vps10 domain proteins, SorL1
[2,23-27] and SorCS1 [22]. At least one action of SorL1
involves its function as a retromer adaptor or receptor,
linking APP to Vps35 [2,21]. When the SorL1-APP
interaction is abolished by mutation of the FANSHY
domain in the cytoplasmic tail of SorL1 that specifies its
binding to Vps35, that FANSHY domain mutant is
unable to regulate APP metabolism [21]. In addition to
its role in retromer-mediated retrieval of APP, another
model suggests that SorL1 plays a gating or retention
function for APP at the TGN [27]. The molecular
mechanism for this interaction at the TGN has been
suggested to involve SorL1 and APP interacting together
with the adaptors GGA and PACS-1 to control exit of
APP into the amyloidogenic and non-amyloidogenic
pathways [27]. The two models for SorL1 action (the
retromer model and the TGN retention model) are not
mutually exclusive, and their relative importance
remains unknown.
Regulation of APP sorting and metabolism by protein
phosphorylation
The first and second messengers linked to APP proces-
sing lead to activation of third messenger protein
kinases and protein phosphatases. PKC and ROCK have
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ent effects on APP metabolism, perhaps due to differen-
tial effects on sorting of APP and/or its derivatives. PKC
activates the a-secretase pathway [4-8], while ROCK
inhibits the a-secretase pathway [14]. These protein
kinases and protein phosphatases converge on physiolo-
gical effector substrate phosphoproteins, and the phos-
phorylation status of those effectors typically specifies
their states of activation. Identification of the phospho-
state sensitive effector molecules that modulate APP
metabolism has been challenging. Vps10-domain pro-
teins are outstanding candidates for such effectors. Since
SorL1 has been proposed [2] and recently demonstrated
[21] to act as an adaptor that links APP to the retromer
complex, we began our study of phospho-state regulated
APP metabolism by Vps10 domain proteins with the
current study of SorL1.
SorL1 is a phosphoprotein
Phospho-site consensus motif software that identifies
the presence of known consensus kinase recognition
motifs [28] revealed multiple putative phosphorylation
sites in the SorL1 cytoplasmic tail (Figure 1). As men-
tioned above, in addition to these phospho-acceptor
consensus motifs, a motif in the SorL1 cytoplasmic tail
has been recently identified that is essential for its inter-
action with Vps35 [21]. This motif, 2172 Phe-Ala-Asn-
Ser-His-Tyr 2173 (FANSHY), is flanked by consensus
sites for PKC phosphorylation at serines 2167 and 2178.
The FANSHY domain is of particular relevance since
the mutations of this motif that abolish SorL1-Vps35
interaction also abolish the ability of SorL1 to control
APP processing [21]. These observations raised the
possibility that the phosphorylation status surrounding
the FANSHY domain might play a key role in the mod-
ulation of APP metabolism by SorL1. In order to begin
to test this hypothesis, we first sought to determine
whether SorL1 is itself a phosphoprotein.
To determine whether SorL1 is a phosphoprotein, we
investigated the electrophoretic migration pattern of
SorL1 on low percentage SDS PAGE before and after
dephosphorylation. SorL1 immunopositive bands follow-
ing a mock reaction without calf intestine alkaline phos-
phatase (CIP) revealed three SorL1 immunopositive
species migrating at approximately 250-270 kDa that
were independently detected with two different anti-
SorL1 antibodies. Upon dephosphorylation with CIP, the
electrophoretic migration pattern shifted dramatically,
and the highest molecular weight species of SorL1
shifted and co-migrated with the lower molecular
weight, immature species (Figure 2A). This behavior was
consistent with the possibility that SorL1 is a phospho-
protein, and that the slower migrating SorL1 species
was modified by the addition of one or more phosphate
moieties.
In order to seek independent confirmatory evidence
that SorL1 is a phosphoprotein, we employed the ProQ
Diamond phospho-stain (Invitrogen) that specifically
detects phosphorylated proteins in polyacrylamide gels.
ProQ detected multiple bands of approximately 250 kDa
that co-migrated with the high molecular weight candi-
date phospho-SorL1, and these were abolished following
treatment with CIP (Figure 2A).
We also sought to determine whether the high mole-
cular weight candidate phospho-SorL1 could be detected
with a specific phospho-serine antibody. Immunoblot-
ting of untreated and CIP-treated lysates revealed
immunopositive bands with the same migratory pattern
Figure 1 The SorL1 cytoplasmic tail contains multiple putative kinase recognition motifs. Analysis of the SorL1 cytoplasmic domain using
phospho-motif software that reports the presence of literature-derived consensus recognition motifs for protein kinases [28] revealed multiple
putative phosphorylation sites. Recognized motifs include three for PKC/PKA [R/K XX S/T] [S/T X R/K] at 2167, 2183 and 2178 (bold black) and
three for CK2 [S/T XX E/D] at 2167, 2187, 2206 (circled bold black) and one for ROCK2 (circled).
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species were not detected with this antibody following
dephosphorylation with CIP (Figure 2B). Taken together,
the altered migration of SorL1 following dephosphoryla-
tion and the staining with both a phospho-stain and
with anti-phospho-serine antibodies support the conclu-
sion that SorL1 is a phosphoprotein.
PKC activation stimulates SorL1 phosphorylation
PKC activates a-secretase-mediated ectodomain shedding
of APP, and a number of g-secretase substrates, including
the Vps10 family members sortilin, SorL1, SorCS1, 2 and
3 [8,23]. Therefore, we sought to determine whether
SorL1 phosphorylation was enhanced following stimula-
tion of PKC. As previously reported, phorbol-12,14-
dibutyrate (PDBu, Sigma), a PKC activator, stimulates
ectodomain shedding of APP and other g-secretase sub-
strates including SorL1 [8,23] (Figure 3A). Treatment of
mouse embryonic fibroblasts (MEFs) with PDBu increased
shedding of the ectodomains of SorL1 and APP, and that
effect was greater following treatment with the combina-
tion of PDBu and okadaic acid (OA), an inhibitor of pro-
tein phosphatases 1 and 2A (Figure 3A, B). Interestingly,
upon treatment with PDBu, the highest molecular weight
SorL1 species (upper two bands) showed increased signal
intensity (Figure 3B) and migration of the SorL1 CTF was
slightly retarded compared to untreated control (Figure 3A),
consistent with the shifts expected for proteins follow-
ing addition of phosphate moieties.
Taken together with our previous observations, these
data suggest that PKC activation results in increased
phosphorylation and ectodomain shedding of SorL1. We
cannot yet determine how SorL1 shedding influences its
ability to regulate Ab. Further study is required to deter-
mine whether PKC does indeed directly phosphorylate
SorL1, and, if so, whether this addition of phosphate to
SorL1 is essential for regulation of soluble SorL1 and
APP shedding and/or Ab generation. The role of the
proximity of the FANSHY domain to the potential
phosphorylation sites also remains to be explored.
SorL1 interacts with ROCK2
We have previously reported that ROCK1 inhibits basal
and statin-activated a-secretase cleavage and shedding of
sAPPa [14]. While ROCK1 is highly expressed in lung,
heart, stomach, liver, kidney, placenta, and testis, it is the
ROCK2 isoform that is more abundant in the heart and
brain [29], suggesting that the actions of ROCK in the
brain may be mediated primarily by the ROCK2 isoform.
We investigated the possibility that ROCK2 interacts with
SorL1. Immunoprecipitation of SorL1 resulted in
co-immunoprecipitation of ROCK2 (Figure 4A). To con-
firm this interaction, we performed the reverse immuno-
precipitation and, indeed, SorL1 was recovered from the
anti-ROCK2 immunoprecipitate but not from the control
IgG immunoprecipitate (Figure 4B). Though we did not
assess whether ROCK2 could regulate phosphorylation of
SorL1, Herskowitz et al (2010) [30] recently reported that
ROCK2 modulates SorL1 phosphorylation, consistent with
our observation that the two molecules can exist as a com-
plex. As with PKC phosphorylation of the SorL1 cytoplas-
mic tail, the possible phospho-state-sensitive modulation
Figure 2 SorL1 is a phosphoprotein. Wt MEFs were grown to confluency and equal concentrations of protein lysate were incubated with (+)
or without (-) calf intestine alkaline phosphatase (CIP). Equal volumes were subsequently analyzed in parallel by immunoblotting with either; a-
SorL1 antibody (BD biosciences), phosopho-serine or ProQ diamond phospho-stain (Invitrogen). A. Separation of samples by 6% SDS PAGE
resulted in identification of multiple SorL1 immunopositive bands (-). Following treatment with CIP (+) (first panel) the largest molecular weight
SorL1 immunopositive band was seen to decrease in molecular weight and as a consequence migrate with the two faster migrating bands.
Detection with ProQ diamond phospho stain that selectively stains phosphoproteins in polyacrylamide gels detected a signal in only the
untreated sample (-) as detected by UV transillumination (second panel). B. Immunoblotting of independent CIP treated lysates revealed
phospho-serine immunopositive bands (right panel) with the same migratory pattern as SorL1 positive bands. To confirm that the phospho-
serine antibody was cross-reacting with SorL1, the phospho-serine immunoblot was stripped and reprobed with a-SorL1 antibody.
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be elucidated. Given their differential effects on APP meta-
bolism [[14], this paper], it is tempting to speculate that
differential phosphorylation of SorL1 by PKC and/or
ROCK1 may be involved.
Inhibition of ROCK2 increases Ab generation
Having identified ROCK2 as a SorL1 binding protein,
we next sought to determine the effect of ROCK2 activ-
ity on Ab generation. Treatment of mouse N2a APPS-
weΔ9PS1 neuroblastoma cells for 100 mins with the
Figure 4 SorL1 interacts with ROCK2. A. Endogenous SorL1 was immunoprecipitated from Wt MEFs using a SorL1 antibody (BD biosciences)
or control IgG. Immunooprecipitates were subjected to SDS-PAGE, transferred to PVDF membranes and probed a-ROCK2. ROCK2 was detected
in the a-SorL1 precipitate. B. Immunoprecipitation of ROCK2 using a-ROCK2 antibody (BD biosciences) resulted in co-immunoprecipitation of
SorL1.
Figure 3 Activation of PKC stimulates SorL1 ectodomain shedding and SorL1 phosphorylation. Wt MEFs were grown to confluency and
incubated for 10 min in the presence of vehicle (-), 1 uM PDBu and/or 1 uM Okadaic acid (OA) (+). Equal volumes of media and protein lysate
were subjected to SDS PAGE, transferred to PVDF and probed with a-SorL1 (N-terminal BD Biosciences) to detect holo SorL1 and the soluble
SorL1 (sSorL1) shed ectodomain, or a-SorL1 C-terminus (J. Lah, Emory) to detect SorL1 CTFs and a-actin as a loading control. A. Treatment with
1 μM PDBu (PKC activator) alone and in combination with 1 uM Okadaic acid, increased ectodomain shedding of SorL1 (sSorL1) and sAPPa into
the media and increased SorL1 cell associated CTF generation. The migration of the SorL1 CTF appeared slightly retarded upon stimulation of
PKC and inhibition of PP1 and PP2A. B. Treatment of lysates with 1 μM PDBu increased levels of the largest molecular weight immunopositive
SorL1 species.
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increased generation of both Ab40 (p =0 . 0 0 7 )a n d
Ab42 (p = 0.03) (Figure 5A). To confirm this observa-
tion and rule out off-target affects of RL1, we next
assessed the effect of specific shRNA lentiviral mediated
knockdown of ROCK2. Transduction with shRNA
ROCK2 (but not with the scrambled shRNA control)
resulted in increased generation of both Ab and sAPPa
in 4 different shRNA ROCK2 reactions (Figure 5B, C).
Like most protein kinases, ROCK autophosphorylates
itself, and the phospho-form is the more active form.
The absence of perfect dose-dependence between
ROCK2 knockdown and Ab generation in Figure 5 may
be due to differences in ROCK2 specific activity related
to differences in phosphorylation status. Phospho-
ROCK2-specific antibodies are being developed to clarify
this point.
While the inhibitor and shRNA sequence used in this
study are specific for ROCK2 when known substrates
are studied, the two isoforms show significant homology,
and we therefore cannot completely rule out non-speci-
fic effects and/or effects mediated by ROCK1.
Conclusions
The involvement of the Rho/ROCK pathway in AD has
been reported by several research groups [14,31,32]. How-
ever, the mechanisms by which ROCK regulates APP pro-
cessing and Ab generation are not well understood.
Figure 5 Inhibition of ROCK2 increases Ab40 and Ab42 generation. A. N2A APPSweΔ9PS1 cells were grown to confluency and treated with
vehicle or 100 nM RL-1 for 60 mins. After 60 mins equal volumes of media were collected and Ab40 and Ab42 levels were determined by
sandwich ELISA (Wako). Ab40 (p = 0.007) and Ab42 (p = 0.03) levels were increased following treatment with 100 nM of the specific ROCK2
inhibitor, RL-1. Data was collected in duplicate or triplicate from 3 independent iterations (*p > 0.05 **p < 0.01). B. N2A APP SweΔ9PS1 cells
were transduced with non-specific scrambled shRNA or 4 different shRNA ROCK2. 72 hrs post transduction media and cell lysates were collected
and snap frozen. Equal volume and concentrations of media and lysate respectively were analyzed by SDS PAGE and transferred to PVDF.
Lysates were analyzed for ROCK2 and GFP as a control for transduction efficiency and media analyzed for sAPPa and Ab. Protein levels are
expressed as percentage of non-transduced C (C). Knockdown of ROCK2 resulted in increased generation of Ab and sAPPa with all shRNA
ROCK2 viruses analyzed but not after transduction with the scrambled non-specific control shRNA.
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dominant negative (DN) ROCK1 increased sAPPa,A b
generation was not addressed in that system [14]. In the
current study, we observed that shRNA mediated knock-
down of ROCK2 resulted in increased release of both
sAPPa and Ab. While the increase in sAPPa is consistent
with our earlier ROCK1 DN data [14] the increase in Ab
is unexpected. One explanation may lie in the mechanism
and subcellular localization by which SorL1 regulates Ab
generation. This is the first example of a protein kinase
that regulates both a-a n db-secretase pathways in parallel.
These data can be construed to fit either the TGN
model of SorL1 action or the retromer model. SorL1-
phospho-state-dependent dissociation of APP and/or
CTFs bound in complexes localized to either the TGN or
to the retromer would be expected to increase substrate
available for generation of sAPPa and Ab. However, the
net effect on APP metabolism would also have to take into
account any actions related to the phosphorylation status
of APP serine-655 [15]. Additional data will be required in
order to develop a model that takes into account all rele-
vant molecules and their phosphorylation status.
Further investigation is required to establish the roles
of ROCK2, PKC and various Vps10 domain proteins in
the phospho-state sensitive generation of Ab generation.
Work by Small et al (2005) [20], Muhammad et al.,
(2009) [33], and Andersen et al., (2010) [21] have
demonstrated the importance of the retromer, and it
will be important to elucidate the possible role of direct
phosphorylation of Vps35 and Vps10-domain receptors.
Ultimately the regulation of APP metabolism by protein
phosphorylation provides an indirect pathway for thera-
peutic modulation of Ab generation. The recent evi-
dence that Ab plays a physiological role in normal
memory formation and the recent failure of a g-secretase
inhibitor in phase 3 clinical trials has pointed up the
necessity for fine regulation of Ab metabolism in order
to balance the requirement for Ab levels that support
memory function against the therapeutic goal of avoiding
Ab accumulation. Targeting a protein phosphorylation
regulatory pathway for APP metabolism may enable finer
adjustment than that achievable by direct inhibition of
b-o rg-secretase.
Balancing between a and b secretase pathways phy-
siology and pathophysiology will be especially important
given the likelihood that Ab-lowering drugs may well be
administered prophylactically to people with intact cog-
nition and then maintained for several decades.
Materials and methods
Antibodies
a-SorL1 (N-terminal, BD Biosciences), a-ROCK2 (BD-
Biosciences), a-actin (Sigma), a-phospho-serine anti-
body (Abcam), a-GFP (Sigma), 6E10 (Covance, sAPPa
and Ab), anti-mouse, anti-rabbit HRP conjugates (Vec-
tor Labs) were purchased. a-SorL1 (C-terminal, gift
from J. Lah, Emory University) to detect SorL1 C-
terminal fragments (CTFs), Ab369 (C-terminal APP
antibody) to detect human holoAPP and C-terminal
fragments [5] were kindly donated. Pro-Q Diamond
phosphoprotein Gel stain (Invitrogen) was used to
detect putative phosphorylated proteins as per the man-
ufacturers instructions.
Cell culture studies
Human embryonic kidney 293 cells and wild type (Wt)
mouse embryonic fibroblasts (MEF) cells were cultured
at 37°C/5%CO2 in growth medium (DMEM, 10%FBS,
1% penicillin/streptomycin, 1%L-glutamine Gibco).
Mouse N2a neuroblastoma cells stably co-transfected
with the FAD mutant forms of APP and PS1 (N2a
APPSweΔ9PS1) (gift from G. Thinakaran, University of
Chicago, Chicago, IL.), were maintained in DMEM sup-
plemented with 10% FBS, penicillin (100 U/ml), strepto-
mycin (100 mg/ml), geneticin (200 mg/ml), and
puromycin (5 mg/ml).
Wildtype MEFs were used for SorL1 phosphorylation
and processing studies, N2a APPSwe ΔE9 PS1 were
used for investigation for pharmacological inhibition of
ROCK2 and shRNA knockdown studies and HEK 293t
cells were used to generate scramble shRNA and
ROCK2 shRNA lentivirus.
Pharmacological studies
Wildtype MEFs were treated in serum free DMEM with
either PDBu (PKC activator, Sigma), okadaic acid (OA)
(protein phosphatase 1 (PP1) and 2A (PP2A), Sigma) or
4,5,6,7-Tetrabromobenzotriazole (TBB) (CK2 inhibitor
Tocris Biosciences). At specified time points media was
collected and snap frozen. Cells were harvested in RIPA
buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl, 1 mM
EDTA, 1 mM DTT, 1% NP40, 0.2 mM PMSF, 0.2 mM
Na3VO4,5 0m MN a F ,1 0m MN a 4P2O7 plus Roche
complete EDTA-free protease inhibitor tablet) using
5c y c l e so f2 0sv o r t e x / 5m i ni c ei n c u b a t i o n ,w i t ht h e
exception of alkaline phosphatase (CIP) studies where
protein phosphatases were excluded from the RIPA buf-
fer. Cell debris was removed by centrifugation at 4°C at
10,000× g for 15 min.
Protein concentrations from cell lysates and media
were determined using the Bio-Rad Protein Determina-
tion Kit. Absorbance was read at 595 nm using a Bio-
Rad Microplate Reader (680XR) and analyzed using
Microplate Manager v5.2.1. Samples were subsequently
prepared in 5× Laemmli buffer and boiled at 95°C for
5 minutes. For analyses of different SorL1 immunoreactive
species, lysates and media were separated by tris-glycine
6% and 10% SDS PAGE gels respectively, transferred
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biosciences) which recognizes an epitope in the SorL1
shed ectodomain to detect 1) holo-SorL1 in lysates and 2)
soluble SorL1 (sSorL1) in media samples and a-SorL1
(J. Lah, Emory) to detect the SorL1 CTF.
To detect putative phosphorylated immunopositive
SorL1 species, 60 μg protein lysate was treated with
vehicle or CIP (NEB) according to manufacturers
instructions and subsequently prepared in 1X Laemmli
buffer and analyzed as above.
N 2 aA P P S w eP S 1w e r eg r o w nt o7 0 %c o n f l u e n c y ,
treated with 100 nM of the selective ROCK2 inhibitor
RL-1 or vehicle control (DMSO) for 60 minutes in
serum free DMEM. At 60 mins post treatment, equal
volume of media were collected and snap frozen and
Ab40 and Ab42 levels were determined by the human
Ab (40 and 42) ELISA kit (WAKO), according to the
manufacturer’s instructions. Absorbance was read at
450 nm using a BioRad microplate reader. Results were
normalized to control (pg/mol) and expressed as per-
centage expression of control.
Immunoprecipitations
Wildtype MEFs were grown to confluency and lysates
were prepared as described in the previous section.
A 300 μg aliquot of cell lysate was used for immunopre-
cipitation using A/G plus agarose beads (Santa Cruz)
with either (a) 2 μg of the appropriate primary antibody
(a-ROCK2, a-SorL1) or (b) IgG control antibody
according to the manufacturers instructions. Equal
volumes of IgG and a-SorL1/aROCK2 immunoprecipi-
tation were separated by SDS PAGE, transferred to
PVDF and immunoblotted with a-SorL1 (BD Bios-
ciences) and a-ROCK2 antibodies as indicated.
Lentivirus production and transduction of N2aAPPSwe
Δ9PS1 cells
Lentivirus was produced in the HEK 293 cells as pre-
viously described [34], with a few modifications. In brief,
the HEK cells were plated onto twelve, 15 cm petri-
plates in DMEM supplemented with 10% FBS, penicillin,
and streptomycin. The cells were grown until 60% con-
fluent and co-transfected with three plasmids. Per petri-
plate, approximately 57 μgo fp l a s m i dD N Aw a su s e d
for the transfection: 19 μg of the CMV-driven HIV gag-
pol, tat and rev plasmid [35], 13 μgo ft h eC M V - d r i v e n
vesicular stomatitis virus-G envelope (VSV-G) plasmid
(plasmid kindly provided by Dr. Anthony W.S. Chan,
Emory). The shRNA expressing lentivectors were pre-
pared by Cellogenetics, Inc. (Gaithersburg, MD) and
25 μg of the scramble shRNA (5’-GTTCTCCGA-
ACGTGTCACG-3’) lentivector or the ROCK2 shRNA
(5’-CAATGAAGCTTCTTAGTAA-3’) expression lenti-
vector was used. The media was replaced 24 hours
following the transfection with the 3 plasmids and the
supernatant was harvested 48 hours later. The superna-
tant was filtered using a 0.45 mm pore-sized membrane
and concentrated by centrifuging at 10,000× g for 2
hours at 4°C. Lentiviral titres were determined by infect-
ing the HEK 293 cells with varying concentrations of
the lentivirus in the presence of Polybrene (8 mg/ml;
Sigma Aldrich). The N2aAPPSwe.ΔPS1 cells were
infected at an MOI of 10 in the presence of polybrene.
72 hrs post transduction with sh ROCK2 or scramble
lentivirus, cells were collected in ice-cold PBS, centri-
fuged at 55× g at 4°C for 15 min, and the media were
collected and snap frozen lysates prepared as described
above. The lysate membrane was analyzed by western
blot using pAb369 (APP C-terminal) to detect APP
holoprotein (holoAPP) and a-actin were detected with
the respective relevant primary antibodies, followed by
HRP-conjugated, species-specific secondary antibodies.
Media gels were immunoblotted with 6E10 to detect
sAPP and Ab. Signals were detected using enhanced
chemiluminescence (Pierce). Digital images were cap-
t u r e du s i n gL A S 3 0 0 0( F u j i F i l m ) ,a n da n a l y z e du s i n g
Multi Gauge v3.1 software.
Statistical analysis
Densitometric analysis of western blot bands (D =
[B - AU]/mm
2) was performed using Multigauge v3.1
software (Fujifilm). Levels of ROCK were normalized to
GFP and expressed as percent of control. Total Ab
levels were analyzed by western blot and bands were
normalized to percent control (empty vector). Absolute
Ab40 and Ab42 concentrations were quantitatively
determined by sandwich ELISA (Wako). Independent
samples t-tests (parametric design) were utilized to
determine significant mean differences between groups.
Significance for t-tests are reported with a p < 0.05
using two-tailed tests with an a-level of 0.05. All statisti-
cal analysis was performed using SPSS v18.0 (SPSS Inc,
Chicago, IL).
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